Caregivers’ perceptions of the therapeutic benefits of drug treatments for dementia
- 274 Downloads
Background and aims
To collect opinions, perceptions, and expectations on the therapeutic benefits of drug treatment for dementia and the impact on the care of the patient in a large sample of caregivers. Only few studies deal with this topic in a small number of participants.
This used an ad-hoc online questionnaire to collect the opinions of caregivers of patients with dementia and assess their expectations and perceptions of the therapeutic benefits of drug treatments. The questionnaire was accessible for nearly 4 months on the Federazione Alzheimer Italia website and had three sections: (1) information on the patient with dementia; (2) information on the caregiver’s perception of the therapeutic benefits of drug treatments; (3) information on caregivers. To evaluate the relationship between the caregiver’s expectations of the therapeutic benefits of dementia treatments and some characteristics of the patients and the caregivers, we used the Chi-square test.
During the access time, 439 questionnaires were filled, and 369 were validated for inclusion in the analysis; of these, 329 also had information on caregivers. The expectations of drug treatment effects were not statistically significantly influenced by any variables considered about the patients or the caregivers. Caregivers’ beliefs about the effectiveness of dementia treatment, their expectations and changes in their lives were clear.
This study addresses a gap in knowledge about caregivers’ experiences and their views of drug treatments, and highlights the need for a pharmaceutical treatment that helps to resolve the symptoms and outcomes of dementia.
KeywordsCaregivers Changes of caregivers’ lives Cholinesterase inhibitors Dementia Perception of therapeutic effects
The authors are very grateful for the support of all caregivers.
Conflict of interest
The authors have no conflicts of interest to disclose.
- 1.Prince M, Bryce R, Ferri C (2011) The benefits of early diagnosis and intervention. Alzheimer’s Disease International World Alzheimer Report, pp 1–72Google Scholar
- 2.Vellone E, Piras G, Venturini G, Alvaro R, Zichi Cohen M (2011) The experience of quality of life for caregivers of people with Alzheimer’s disease living in Sardinia, Italy. J Transcult Nurs XX(X):1–10Google Scholar
- 3.Birks J (2006) Cholinesterase inhibitors for Alzheimer’s disease. In Cochrane database of systematic reviews 2006: issue 1. Art. no. CD005593. Wiley, New York. doi: 10.1002/14651858.CD005593
- 5.Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P, AD2000 Collaborative Group (2004) Long-term donepezil treatment in 565 patients with Alzheimer’s disease: randomised double-blind trial. Lancet 363(9427):2105–2115PubMedCrossRefGoogle Scholar
- 9.Society Alzheimer’s (2000) Appraisal of the drugs for Alzheimer’s disease: submission to the National Institute for Clinical Excellence (NICE). Alzheimer’s Society, LondonGoogle Scholar
- 10.Society Alzheimer’s (2004) Drugs for the treatment of Alzheimer’s disease. Alzheimer’s Society, LondonGoogle Scholar
- 12.Shua-Haim JR, Comsti R, Shua-Haim V, Ross JS (1997) Donepezil (Aricept): the caregivers voices and clinical impression. Am J Alzheimer’s Dis 12:272–279Google Scholar
- 13.McAvinchey K, Burns A (2009) Perceived efficacy of antidementia drug treatment. Nat Rev 5:302–303Google Scholar